Q3 2024 Sedana Medical AB (publ) Earnings Call(Q&A) Transcript
Key Points
- Sedana Medical AB (FRA:7D2A) reported its highest Q3 net sales in history, reaching SEK 40 million, marking a 20% year-over-year growth excluding currency effects.
- The company raised its full-year sales guidance to 17% to 20%, up from the previous 14% to 18%, due to strong performance across all regions.
- Enrollment for both Phase III trials in the U.S. is completed, which is expected to significantly reduce cash burn in the coming year.
- Sedana Medical AB (FRA:7D2A) signed an agreement to acquire its main supplier, Innovatif Cekal, which is projected to add 2 percentage points to EBITDA over time.
- The company has a strong market potential in the U.S., estimated at SEK 10 billion to SEK 12 billion, with a favorable product-market fit and a supportive network of key opinion leaders.
- The integration of the European clinical trial into the U.S. submission will delay the timeline by approximately a year and add SEK 20 million to SEK 30 million in additional costs.
- Despite improved EBITDA margins, Sedana Medical AB (FRA:7D2A) remains in negative territory, with a group EBITDA of negative SEK 9 million for Q3 2024.
- The company's cash and cash equivalents decreased significantly from SEK 304 million to SEK 226 million this quarter, raising concerns about cash management.
- France experienced flat sales due to vacancies from sick leave, impacting promotional activities and sales growth.
- The U.S. FDA submission process carries inherent uncertainties, and any delays could impact revenue projections and market entry timing.
Hello, and welcome to today's webcast presentation with Sedana Medical. With us presenting today, we have the CEO, Johannes Doll; CFO, Johan Spetz; and CMO, Peter Sackey. (Operator Instructions)
And with that said, I'll give the floor to you guys. Please go ahead with your presentation.
()- -
Thank you. A warm welcome to Sedana Medical's Q3 report. Thank you very much for joining us today. As you've heard with me today, I have our Chief Medical Officer, Peter Sackey, who will talk about our progress on the U.S. side in just a little while; and our CFO, Johan Spetz, who will take us through the financial update later on.
If we start on Page 3 please, with the highlights of the third quarter. Our corporate priorities have, of course, remained the same. You have heard me talk about those numerous times now. Number one, achieve steady growth in our existing markets; second, to reach breakeven in our ex-U.S. business as a first important
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
